What's new? Log in Free sign up

Novartis (NVS)

Company Profile

Company profile

Ticker

NVS, NVSEF

Exchange

Website

www.novartis.com

CEO

Dr. Vasant Narasimhan M.D.

Incorporated

Location

Fiscal year end

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co. • Teva Pharmaceutical Industries Limited • Abbott Laboratories • Eli Lilly and • Bristol-Myers Squibb • Viatris • AbbVie • Bausch Health Companies ...

Former names

KRAFT FOODS INC

SEC CIK

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Material Contracts & Credit Agreements

Subsidiaries Lists

NVS stock data

1M 3M 6M 1Y

Latest filings (excl ownership)

View all

Current report (foreign)

Current report (foreign)

Disclosure regarding Iran Threat Reduction and Syria Human Rights Act

Annual report (foreign)

Current report (foreign)

Current report (foreign)

Current report (foreign)

Current report (foreign)

Current report (foreign)

Prospectus supplement for primary offering

Transcripts

View all

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Latest ownership filings

View all

Notice of proposed sale of securities

Notice of proposed sale of securities

Financial summary

Financial statements Chart NVS financial data

Quarter (USD)	Dec 24	Dec 23	Dec 22	Dec 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 24	Dec 23	Dec 22	Dec 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from Novartis earnings reports.

Institutional ownership, Q4 2024

NVS institutional ownership history Ownership history

6.6% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	1295	1281	+1.1%
Opened positions	148	102	+45.1%
Closed positions	134	106	+26.4%
Increased positions	407	407	–
Reduced positions	455	460	-1.1%

13F shares	Current	Prev Q	Change
Total value	11.72 tn	13.84 tn	-15.4%
Total shares	129.68 mm	130.44 mm	-0.6%
Total puts	1.56 mm	1.83 mm	-14.7%
Total calls	1.31 mm	1.12 mm	+17.9%
Total put/call ratio	1.2	1.6	-27.7%

Largest owners	Shares	Value	Change
Dodge & Cox	12.21 mm	$1.19 tn	-0.1%
Primecap Management	11.03 mm	$1.07 tn	-8.2%
Dimensional Fund Advisors	8.18 mm	$796.37 bn	+1.1%
MS Morgan Stanley	6.87 mm	$668.44 bn	-1.7%
Loomis Sayles & Co L P	5.58 mm	$542.69 mm	-3.3%
BAC Bank of America	4.55 mm	$442.64 bn	-8.4%
BEN Franklin Resources	4.36 mm	$423.84 bn	-0.5%
Wellington Management	3.65 mm	$354.97 bn	-8.8%
Renaissance Technologies	2.67 mm	$259.71 bn	+16.0%
PFG Principal Financial	2.43 mm	$236.16 bn	-1.7%

Largest transactions	Shares	Bought/sold	Change
GS The Goldman Sachs Group, Inc.	2.28 mm	-1.20 mm	-34.5%
Primecap Management	11.03 mm	-983.02 k	-8.2%
RJF Raymond James Financial	907.81 k	+907.81 k	NEW
Arrowstreet Capital, Limited Partnership	11.05 k	-888.87 k	-98.8%
Mondrian Investment Partners	658.00 k	+658.00 k	NEW
D. E. Shaw & Co.	612.38 k	+563.96 k	+1164.6%
Raymond James & Associates	0.00	-518.18 k	EXIT
Qube Research & Technologies	634.57 k	+476.42 k	+301.2%
BAC Bank of America	4.55 mm	-415.53 k	-8.4%
Citadel Advisors	588.19 k	+406.01 k	+222.9%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

News

From Benzinga Pro

'Novartis Sees Radioactive Cancer Drugs Becoming $10B Business: CEO' - Nikkei Asia

https://asia.nikkei.com/Business/Pharmaceuticals/Novartis-sees-radioactive-cancer-drugs-becoming-10bn-business-CEO

Teladoc Health Partners With Eli Liily's LillyDirect to Expand Access to Zepbound For Weight Loss

Teladoc Health teams up with Eli Lilly's LillyDirect to improve Zepbound access, offering direct home delivery and comprehensive obesity care support.

'Novartis To Mass Produce Next-Generation Cancer Drugs In Japan' - Nikkei Asia

https://asia.nikkei.com/Business/Pharmaceuticals/Novartis-to-mass-produce-next-generation-cancer-drugs-in-Japan

Roche Touts Food Allergy Drug As Superior Than Oral Immunotherapy

Court Dismisses Novartis Challenge To Medicare Drug Price Negotiation Program

Press releases

From Benzinga Pro

Novartis data presentations at AAAAI and AAD underscore commitment to advancing treatment of hidradenitis suppurativa (HS) and chronic spontaneous urticaria (CSU)

Two-year efficacy and safety data analyses from Phase III SUNSHINE and SUNRISE trials of continuous Cosentyx® (secukinumab) treatment in HS to be presentedNew analyses of 52-week data from Phase III REMIX pivotal

GeminiBio Appoints Mike Stella to Board

Strengthening Board with Industry Veterans Gemini Bioproducts, LLC ("GeminiBio"), a biopharma and advanced therapy raw materials supplier, and a portfolio company of BelHealth Investment Partners, LLC ("BelHealth"), a

Promising Data for Treating Gastrointestinal Cancer Leading to Hopeful Advancements for Pancreatic & Anal Cancers

PALM BEACH, Fla., Dec. 18, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - One of the most common malignancies in the world today is gastric cancer. The incidence rate is influenced by various factors,

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.